Straits Times Index
3,301.78 +4.23 (+0.13%) S&P 500
5,482.95 +9.72 (+0.18%) Dow
38,797.93 +19.83 (+0.05%) Nasdaq
17,871.62 +14.61 (+0.08%) Bitcoin USD
64,547.02 -781.36 (-1.20%) CMC Crypto 200
1,346.05 -43.35 (-3.12%)
EDIT Jul 2024 4.000 call
| Previous close | 1.8000 |
| Open | N/A |
| Bid | 0.8500 |
| Ask | 2.7000 |
| Strike | 4.00 |
| Expiry date | 2024-07-05 |
| Day's range | 1.8000 - 1.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
ZacksEditas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
GlobeNewswireEditas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%. Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA RUBY oral pres
- GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA EdiTHAL poster presentation on Friday, June 14 at 6 p.m. CEST/Noon EDT CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.
